Zobrazeno 1 - 10
of 4 560
pro vyhledávání: '"Michael Mosley"'
Autor:
Chung Ying Chan, Samantha L. Hopkins, Florian Guibbal, Anna Pacelli, Julia Baguña Torres, Michael Mosley, Doreen Lau, Patrick Isenegger, Zijun Chen, Thomas C. Wilson, Gemma Dias, Rebekka Hueting, Véronique Gouverneur, Bart Cornelissen
Publikováno v:
EJNMMI Research, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Purpose Radiopharmaceuticals targeting poly(ADP-ribose) polymerase (PARP) have emerged as promising agents for cancer diagnosis and therapy. PARP enzymes are expressed in both cancerous and normal tissue. Hence, the injected mass, molar acti
Externí odkaz:
https://doaj.org/article/4fdd5e6fe6fb4606aa18d95a3283dafa
Publikováno v:
Theranostics, 13(4), 1302-1310. IVYSPRING INT PUBL
Rationale: An effective absorbed dose response relationship is yet to be established for Lutetium-177 based radionuclide therapies such as 177Lu-DOTATATE and 177Lu-PSMA. The inherent biological heterogeneity of neuroendocrine and prostate cancers may
Autor:
Michael Mosley
Publikováno v:
Mail on Sunday. 10/13/2024, p38. 2p.
Autor:
MICHAEL MOSLEY
Publikováno v:
Daily Mail. 1/27/2024, p50. 3p.
Autor:
DR MICHAEL MOSLEY
Publikováno v:
Daily Mail. 1/9/2024, p22. 3p.
Autor:
MICHAEL MOSLEY
Publikováno v:
Daily Mail. 1/2/2024, p28. 3p.
Autor:
Michael Mosley
Publikováno v:
Mail on Sunday. 2/4/2024, p20. 3p.
Autor:
Michael Mosley
Publikováno v:
Mail on Sunday. 1/28/2024, p34. 3p.
Autor:
Gianluca Destro, Zijiun Chen, Chung Ying Chang, Claudia Fraser, Gemma Dias, Michael Mosley, Florian Guibbal, Veronique Gouverneur, Bart Cornelissen
Publikováno v:
Nuclear medicine and biology.
Introduction: Radioligand therapy (RLT) is an expanding field that has shown great potential in the fight against cancer. Radionuclides that can be carried by selective ligands such as antibodies, peptides, and small molecules targeting cancerous cel
Autor:
Chung Ying Chan, Samantha L. Hopkins, Florian Guibbal, Anna Pacelli, Julia Baguña Torres, Michael Mosley, Doreen Lau, Patrick Isenegger, Zijun Chen, Thomas C. Wilson, Gemma Dias, Rebekka Hueting, Véronique Gouverneur, Bart Cornelissen
Publikováno v:
EJNMMI Research, 12(1):67. SpringerOpen
Purpose Radiopharmaceuticals targeting poly(ADP-ribose) polymerase (PARP) have emerged as promising agents for cancer diagnosis and therapy. PARP enzymes are expressed in both cancerous and normal tissue. Hence, the injected mass, molar activity and